ArticleTheranostics2024
[
Article in Theranostics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Beyond [BMC cancer · 2026Pooled it
- Efficacy and safety of [Frontiers in medicine · 2026Pooled it
- Investigating the significance of SPECT/CT-SUV for monitoringBMC medical imaging · 2025Pooled it
- PSMA-targeted radioligand therapy in prostate cancer: evidence hierarchy, platform maturity of ¹⁷⁷Lu-PSMA-617, and the clinical differentiation challenge for emerging radionuclides.Annals of nuclear medicine · 2026Review
- Evaluation of treatment efficacy of theEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Organ and tumor dosimetry of [European journal of nuclear medicine and molecular imaging · 2026Article
- Tolerability of [European journal of nuclear medicine and molecular imaging · 2026Article
- High-yield reactor production of terbium-161 using thin-layer gadolinium-160 targets, simplified chloride based separation and radiolabeling of DOTA based ligands.EJNMMI radiopharmacy and chemistry · 2026Article
- Auger-Emitting Radionuclides in Radiopharmaceutical Research: Decay-Associated Processes, Vector-Dependent Localization, and Translational Perspectives.International journal of molecular sciences · 2026Review
- Outcome and Safety of Radioligand Therapy With [ 161 Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [ 177 Lu]Lu-PSMA-617.Clinical nuclear medicine · 2026Observational
- QuantitativeEJNMMI physics · 2026Article
- Tellurium-118 as a novel radionuclide for long-term positron emission tomography.Scientific reports · 2026Article
- Comparative theranostic efficacy ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- First Southeast Asian Experience of Terbium-161 PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Quantitative Imaging and Dosimetric Approach.Molecular imaging and radionuclide therapy · 2026Article
- Quantitative performance of a 3D CZT and conventional SPECT/CT for Tb-161 imaging.EJNMMI physics · 2026Article
- Head-to-head comparison of [EJNMMI research · 2026Article
- PSMA-targeted radioligand therapy with beta emitters in prostate cancer: current evidence, emerging indications, combination strategies, and future directions.Frontiers in medicine · 2026Review
- Contemporary opportunities and potential of Auger electron-emitting theranostics.Theranostics · 2026Review
- Optimization of the radiosynthesis of the PSMA-targeting drugs [EJNMMI radiopharmacy and chemistry · 2025Article
- The Role of Nuclear Medicine in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.